Cell Damage–Like Proteomic Signatures Distinguish Cell‐Free and Concentrated Ascites Reinfusion Therapy ( CART ) Membranes in Malignant Ascites: A Mechanistic Study
Therapeutic Apheresis and Dialysis · 26.07.2026
DOI: 10.1002/1744-9987.70201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 26.07.2026. Verfasst von Masaki Nojima und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Asahi Kasei Medical Corporation.
Abstract (Originalsprache)
Introduction
Cell‐free and concentrated ascites reinfusion therapy (CART) alleviates the symptoms of malignant ascites but may trigger inflammation. We investigated why AHF‐MO filter (A‐A)–processed concentrates showed weaker bioactivity than EC20W filter (A‐E)–processed concentrates.
Methods
Ascites from three patients with ovarian cancer were processed into untreated ascites (UA), A‐A, or A‐E. Whole ascites, extracellular vesicles (EVs), and EV‐depleted supernatants were injected intraperitoneally into mice. Serum cytokines were measured, and label‐free proteomics was used to identify inflammatory pathways.
Results
A‐E induced the strongest proinflammatory and Th17/type I interferon responses compared to UA. A‐A produced intermediate activation. EV‐depleted A‐E supernatants remained highly bioactive. A‐E was enriched in proteins associated with cellular damage pathways and proinflammatory signaling. A‐A exhibited attenuated changes and preserved regulatory proteins.
Conclusion
A‐A yields a more balanced inflammatory and proteomic profile than A‐E. Our findings provide a preliminary mechanistic rationale for its use in CART and offer targets for membrane optimization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
- Clinical Engineering Department, Juntendo University Hospital, Tokyo, Japan.
- Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
- Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
ORCID-Profile: Masaki Nojima, Goh Murayama, Sumio Ohtsuki, Akira Uchiyama, Takumi Saito, Makio Kusaoi, Yasuhisa Terao, Atsuo Itakura, Kenichi Ikejima, Naoto Tamura, Ken Yamaji
Förderung
- Asahi Kasei Medical Corporation
Zitieren
APA
Nojima, M., Murayama, G., Inoue, M., Urita, T., Ohtsuki, S., Hirayama, T., Uchiyama, A., Yamaji, Y., Hagiwara, Y., Saito, T., Kuga, T., Miyashita, T., Kusaoi, M., Terao, Y., Itakura, A., Ikejima, K., Tamura, N., & Yamaji, K. (2026). Cell Damage–Like Proteomic Signatures Distinguish Cell‐Free and Concentrated Ascites Reinfusion Therapy ( CART ) Membranes in Malignant Ascites: A Mechanistic Study. Therapeutic Apheresis and Dialysis. https://doi.org/10.1002/1744-9987.70201
Vancouver
Nojima M, Murayama G, Inoue M, Urita T, Ohtsuki S, Hirayama T, et al. Cell Damage–Like Proteomic Signatures Distinguish Cell‐Free and Concentrated Ascites Reinfusion Therapy ( CART ) Membranes in Malignant Ascites: A Mechanistic Study. Therapeutic Apheresis and Dialysis. 2026. doi:10.1002/1744-9987.70201
BibTeX
@article{Nojima2026,
author = {Nojima, Masaki and Murayama, Goh and Inoue, Moeko and Urita, Takuya and Ohtsuki, Sumio and Hirayama, Takashi and Uchiyama, Akira and Yamaji, Yu and Hagiwara, Yukitomo and Saito, Takumi and Kuga, Taiga and Miyashita, Tomoko and Kusaoi, Makio and Terao, Yasuhisa and Itakura, Atsuo and Ikejima, Kenichi and Tamura, Naoto and Yamaji, Ken},
title = {Cell Damage–Like Proteomic Signatures Distinguish Cell‐Free and Concentrated Ascites Reinfusion Therapy ( CART ) Membranes in Malignant Ascites: A Mechanistic Study},
journal = {Therapeutic Apheresis and Dialysis},
year = {2026},
doi = {10.1002/1744-9987.70201}
}
EUVIMED